DMAC vs PTC · $157.4M cap vs P/E 48, rev $2.74B
DiaMedica Therapeutics Inc (DMAC) versus PTC Inc (PTC) — a side-by-side from cached financials, not a winner call.
DiaMedica Therapeutics Inc (DMAC) is a biotechnology company listed on US.
PTC Inc (PTC) is a software - application company listed on US.
DMAC does not have a complete income-statement cache yet.
Latest reported PTC revenue for 2025-09-30 was $2.74B. Net income was $734.0M. Revenue was up 19.2% from 2024-09-30 to 2025-09-30. PTC currently screens at market cap $21.11B and trailing P/E 48.3.
DMAC currently screens at market cap $157.4M. PTC currently screens at market cap $21.11B and trailing P/E 48.3.
Not investment advice. Open the DMAC and PTC stock pages for the full models.
Not investment advice.